BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 21642745)

  • 1. Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors.
    Landry F; Chan CC; Huang Z; Leclair G; Li CS; Oballa R; Zhang L; Bateman K
    J Lipid Res; 2011 Aug; 52(8):1494-9. PubMed ID: 21642745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
    Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
    Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
    Dillon R; Greig MJ; Bhat BG
    Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
    Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
    Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
    Yang SM; Tang Y; Rano T; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Lang W; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
    Bioorg Med Chem Lett; 2014 Mar; 24(5):1437-41. PubMed ID: 24405703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1).
    Voss MD; Zoller G; Matter H; Herling AW; Biemer-Daub G; Pfenninger A; Haag-Diergarten S; Keil S; Kohlmann M; Schmidts HL
    Eur J Pharmacol; 2013 May; 707(1-3):140-6. PubMed ID: 23524088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stearoyl-CoA desaturase activity in bovine cumulus cells protects the oocyte against saturated fatty acid stress.
    Aardema H; van Tol HTA; Wubbolts RW; Brouwers JFHM; Gadella BM; Roelen BAJ
    Biol Reprod; 2017 May; 96(5):982-992. PubMed ID: 28486699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
    Liu G
    Curr Top Med Chem; 2010; 10(4):419-33. PubMed ID: 20180759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The biosynthesis of hepatic cholesterol esters and triglycerides is impaired in mice with a disruption of the gene for stearoyl-CoA desaturase 1.
    Miyazaki M; Kim YC; Gray-Keller MP; Attie AD; Ntambi JM
    J Biol Chem; 2000 Sep; 275(39):30132-8. PubMed ID: 10899171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Oleic Acid in the Gut-Liver Axis: From Diet to the Regulation of Its Synthesis via Stearoyl-CoA Desaturase 1 (SCD1).
    Piccinin E; Cariello M; De Santis S; Ducheix S; Sabbà C; Ntambi JM; Moschetta A
    Nutrients; 2019 Sep; 11(10):. PubMed ID: 31554181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipidomic Analysis of α-Synuclein Neurotoxicity Identifies Stearoyl CoA Desaturase as a Target for Parkinson Treatment.
    Fanning S; Haque A; Imberdis T; Baru V; Barrasa MI; Nuber S; Termine D; Ramalingam N; Ho GPH; Noble T; Sandoe J; Lou Y; Landgraf D; Freyzon Y; Newby G; Soldner F; Terry-Kantor E; Kim TE; Hofbauer HF; Becuwe M; Jaenisch R; Pincus D; Clish CB; Walther TC; Farese RV; Srinivasan S; Welte MA; Kohlwein SD; Dettmer U; Lindquist S; Selkoe D
    Mol Cell; 2019 Mar; 73(5):1001-1014.e8. PubMed ID: 30527540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic stearoyl CoA desaturase 1 deficiency increases glucose uptake in adipose tissue partially through the PGC-1α-FGF21 axis in mice.
    Aljohani A; Khan MI; Bonneville A; Guo C; Jeffery J; O'Neill L; Syed DN; Lewis SA; Burhans M; Mukhtar H; Ntambi JM
    J Biol Chem; 2019 Dec; 294(51):19475-19485. PubMed ID: 31690632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
    Uto Y
    Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thia fatty acids as substrates and inhibitors of stearoyl-CoA desaturase.
    Høvik KE; Spydevold OS; Bremer J
    Biochim Biophys Acta; 1997 Nov; 1349(3):251-6. PubMed ID: 9434139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cancer cell dependence on unsaturated fatty acids implicates stearoyl-CoA desaturase as a target for cancer therapy.
    Roongta UV; Pabalan JG; Wang X; Ryseck RP; Fargnoli J; Henley BJ; Yang WP; Zhu J; Madireddi MT; Lawrence RM; Wong TW; Rupnow BA
    Mol Cancer Res; 2011 Nov; 9(11):1551-61. PubMed ID: 21954435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo antitumor activities of T-3764518, a novel and orally available small molecule stearoyl-CoA desaturase 1 inhibitor.
    Nishizawa S; Sumi H; Satoh Y; Yamamoto Y; Kitazawa S; Honda K; Araki H; Kakoi K; Imamura K; Sasaki M; Miyahisa I; Satomi Y; Nishigaki R; Hirayama M; Aoyama K; Maezaki H; Hara T
    Eur J Pharmacol; 2017 Jul; 807():21-31. PubMed ID: 28442322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension.
    Bellenger J; Bellenger S; Clément L; Mandard S; Diot C; Poisson JP; Narce M
    FASEB J; 2004 Apr; 18(6):773-5. PubMed ID: 14977874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.
    Lachance N; Gareau Y; Guiral S; Huang Z; Isabel E; Leclerc JP; Léger S; Martins E; Nadeau C; Oballa RM; Ouellet SG; Powell DA; Ramtohul YK; Tranmer GK; Trinh T; Wang H; Zhang L
    Bioorg Med Chem Lett; 2012 Jan; 22(2):980-4. PubMed ID: 22209206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.
    Ramtohul YK; Powell D; Leclerc JP; Leger S; Oballa R; Black C; Isabel E; Li CS; Crane S; Robichaud J; Guay J; Guiral S; Zhang L; Huang Z
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5692-6. PubMed ID: 21871798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stearoyl-CoA desaturase as a new drug target for obesity treatment.
    Dobrzyn A; Ntambi JM
    Obes Rev; 2005 May; 6(2):169-74. PubMed ID: 15836467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.